Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Approves Lantheus Imaging Drug for Alzheimer's Diagnostics

15 August 2026 · By · Wire by Fusion42

Published

15 August 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at sahmcapital.com →

◆ Verified

Fusion42 · 16 August 2026 · Fusion42 review

The FDA approved Lantheus Holdings' Tauklarify, a PET imaging drug to detect tau pathology associated with Alzheimer's disease, validating its use in adult patients with cognitive impairment. The approval was supported by clinical studies analyzing brain scans across a range of cognitive states.

This Wire brief sits within Fusion42's coverage of Medtech, and 4 sources have reported it between 14 Aug 2026 and 15 Aug 2026.

◆ ◆ The Wire takeaway

You can now pitch imaging solutions supporting Alzheimer's drug development as FDA validation lowers clinical risk. Broaden your network with pharma partners focused on Alzheimer’s treatments to win early collaborations.

◆ Coverage

4 sources · first reported 14 Aug 2026 · latest 15 Aug 2026

◆ Related on Wire

◆ Topics

Medtechfda-approvalalzheimersimaging-drugmedtechdiagnostics